• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Nature's Sunshine Reports Strong Fourth Quarter and Full Year 2025 Financial Results

    3/10/26 4:05:00 PM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NATR alert in real time by email

    LEHI, Utah, March 10, 2026 (GLOBE NEWSWIRE) -- Nature's Sunshine Products, Inc. (NASDAQ:NATR) ("Nature's Sunshine" and/or the "Company"), a global leader in manufacturing and marketing high-quality herbal and nutritional supplements, reported financial results for the fourth quarter and full year ended December 31, 2025.

    Fourth Quarter 2025 Financial Summary vs. Same Year-Ago Quarter

    • Net sales were up 4.7% to $123.8 million compared to $118.2 million (up 3.8% in constant currency).
    • GAAP net income attributable to common shareholders of $4.1 million, or $0.23 per diluted share, compared to net loss of $0.3 million, or $(0.02) per diluted share.
    • Adjusted EBITDA up 16% to $11.9 million compared to $10.3 million.

    Full Year 2025 Financial Summary vs. 2024

    • Net sales were up 5.7% to $480.1 million compared to $454.4 million (up 5.3% in constant currency).
    • GAAP net income attributable to common shareholders of $19.5 million, or $1.06 per diluted share, compared to $7.7 million, or $0.40 per diluted share.
    • Adjusted EBITDA up 21.7% to $49.4 million compared to $40.5 million.

    Management Commentary

    "We finished a record year in sales and delivered our second‑best quarter ever and our largest Q4 on record, with sales and adjusted EBITDA up 5% and 16%, respectively," said Ken Romanzi, CEO of Nature's Sunshine.

    "We continue to see strong momentum in our Digital strategy, supported by exceptional customer acquisition. In Q4, new customers in our Digital channels grew 98% compared to the prior year, driving a 47% increase in our Digital business and accelerating North America growth to 6%. This digital strength was complemented by solid performance in our core businesses in China, Japan, Korea, and Europe."

    "After my first quarter at Nature's Sunshine, I am even more delighted with the potential of our company. As we look ahead, we are in the early stages of laying the groundwork to accelerate growth across the business driven by continued acceleration into digital channels, driving deeper penetration in our existing markets, expanding into new geographies, introducing more innovative products and unlocking new channels."

    Fourth Quarter 2025 Financial Results

     Net Sales by Operating Segment (Amounts in Thousands)
     Three Months Ended

    December 31, 2025
     Three Months Ended

    December 31, 2024
     Percent

    Change
     Impact of

    Currency

    Exchange
     Percent Change

    Excluding

    Impact of Currency
    Asia$55,735 $56,297 (1.0)% $146 (1.3)%
    Europe 25,171  21,324 18.0   761 14.5 
    North America 37,392  35,130 6.4   3 6.4 
    Latin America and Other 5,509  5,454 1.0   146 (1.7)
     $123,807 $118,205 4.7% $1,056 3.8%
                   

    Net sales in the fourth quarter of 2025 increased 4.7% to $123.8 million compared to $118.2 million in the year-ago quarter. Excluding the impact from foreign exchange rates, net sales in the fourth quarter of 2025 increased 3.8% compared to the year-ago quarter.

    Gross margin in the fourth quarter increased to 72.5% compared to 72.0% in the year-ago quarter, due to cost saving initiatives and market mix.

    Volume incentives as a percentage of net sales decreased to 29.1% compared to 31.1% in the year-ago quarter, due to changes in market mix.

    Selling, general and administrative expenses ("SG&A") in the fourth quarter were $48.4 million compared to $43.7 million in the year-ago quarter. The increase was primarily related to the timing of compensation costs, incremental investment in digital marketing and consultant events, increased service fees due to China's higher net sales, as well as other non-recurring expenses. As a percentage of net sales, SG&A expenses increased to 39.1% in the fourth quarter of 2025 compared to 37.0% in the year-ago quarter.

    Operating income in the fourth quarter was $5.3 million, or 4.3% of net sales, compared to $4.6 million, or 3.8% of net sales, in the year-ago quarter.

    Other income (loss), net, in the fourth quarter of 2025 was $0.2 million compared to $(3.1) million in the year-ago quarter. Other income (loss), net, primarily consisted of foreign exchange gains as a result of net changes in foreign currencies in Asia, Europe and Latin America. The provision for income taxes was $1.0 million in the fourth quarter of 2025 compared to $2.2 million in the year-ago quarter.

    GAAP net income (loss) attributable to common shareholders was net income of $4.1 million, or $0.23 per diluted common share, compared to net loss of $(0.3) million, or $(0.02) per diluted common share, in the year-ago quarter. Net income (loss) attributable to NSP China was $2.0 million, or $0.11 per diluted common share, for the fourth quarter of 2025, compared to net loss of $(2.1) million, or $(0.11) per diluted common share, in the prior year quarter.

    Non-GAAP net income attributable to common shareholders was $5.4 million, or $0.30 per diluted common share, compared to $43,000, or $0.00 per diluted common share, in the year-ago quarter. Adjusted net income, which is a non-GAAP financial measure, is defined here as net income from continuing operations before less-frequent items including, among other things, restructuring expenses and certain tax refunds. A reconciliation of adjusted net income to GAAP net income is provided in the financial tables below.

    Adjusted EBITDA in the fourth quarter increased 16% to $11.9 million compared to $10.3 million in the prior year quarter. Adjusted EBITDA, which is a non-GAAP financial measure, is defined here as net income from continuing operations before taxes, depreciation, amortization, and other income (loss) adjusted to exclude share-based compensation expense and certain noted adjustments. A reconciliation of net income (loss) to Adjusted EBITDA is provided in the attached financial tables.

    Full Year 2025 Financial Results

     Net Sales by Operating Segment (Amounts in Thousands)
     Year Ended

    December 31, 2025
     Year Ended

    December 31, 2024
     Percent

    Change
     Impact of

    Currency

    Exchange
     Percent Change

    Excluding

    Impact of Currency
    Asia$221,777 $207,794 6.7% $668  6.4%
    Europe 93,133  84,837 9.8   1,682  7.8 
    North America 143,611  138,849 3.4   (210) 3.6 
    Latin America and Other 21,623  22,884 (5.5)  (295) (4.2)
     $480,144 $454,364 5.7% $1,845  5.3%
                    

    Net sales in 2025 increased 5.7% to $480.1 million compared to $454.4 million in 2024. Excluding unfavorable foreign exchange rates, net sales in 2025 increased 5.3% compared to the prior year.

    Gross margin in 2025 increased to 72.4% compared to 71.5% in 2024. The increase was due to cost saving initiatives and market mix.

    Volume incentives as a percentage of net sales in 2025 were 30.1% compared to 30.9% in 2024. The slight decrease was primarily due to changes in market mix and the timing of promotional incentives.

    SG&A in 2025 were $178.4 million compared to $164.0 million in 2024. The increase was primarily related to the timing of compensation costs, incremental investment in digital marketing and consultant events, increased service fees due to China's higher net sales, as well as other non-recurring expenses. As a percentage of net sales, SG&A expenses were 37.2% in 2025 compared to 36.1% in 2024.

    Operating income in 2025 was $24.7 million, or 5.1% of net sales, compared to $20.1 million, or 4.5% of net sales, in 2024.

    Other income (loss), net, in 2025 was income of $5.1 million compared to loss of $1.7 million in 2024. Other income (loss), net, primarily consisted of foreign exchange gains as a result of net changes in foreign currencies, in Europe and Asia, partially offset by losses in North America and Latin America and Other. The provision for income taxes was $9.4 million in 2025 compared to $10.5 million in 2024.

    GAAP net income attributable to common shareholders was $19.5 million, or $1.06 per diluted common share, compared to $7.7 million, or $0.40 per diluted common share, in 2024. Net income attributable to NSP China increased to $4.7 million, or $0.25 per diluted common share, for 2025, compared to $1.0 million, or $0.05 per diluted common share, in the prior year.

    Non-GAAP net income attributable to common shareholders in 2025 was $23.3 million, or $1.26 per diluted common share, compared to $8.9 million, or $0.46 per diluted common share, in 2024. Adjusted net income, which is a non-GAAP financial measure, is defined here as net income from continuing operations before less-frequent items including, among other things, restructuring expenses and certain tax refunds. A reconciliation of non-GAAP net income to GAAP net income is provided in the attached financial tables.

    Adjusted EBITDA in 2025 increased 21.7% to $49.4 million compared to $40.5 million in 2024. The increase was driven primarily by the aforementioned increase in operating income. Adjusted EBITDA, which is a non-GAAP financial measure, is defined here as net income from continuing operations before taxes, depreciation, amortization, and other income (loss) adjusted to exclude share-based compensation expense and certain noted adjustments. A reconciliation of net income to Adjusted EBITDA is provided in the attached financial tables.

    Balance Sheet and Cash Flow

    Net cash provided by operating activities was $35.3 million for the year ended December 31, 2025, compared to $25.3 million in the prior year. Capital expenditures during the twelve months ended December 31, 2025, totaled $6.5 million compared to $11.0 million in 2024. During the twelve months ended December 31, 2025, the Company repurchased 1,260,000 shares at a total cost of $16.3 million, or $12.95 per share. As of December 31, 2025, the Company had cash and cash equivalents of $93.9 million and no outstanding debt.

    Outlook

    The Company expects full year 2026 net sales to range between $500 - $515 million and expects adjusted EBITDA to range between $50 - $54 million.

    Conference Call

    The Company will hold a conference call today at 5:00 p.m. Eastern time to discuss its fourth quarter and full year 2025 results.

    Date: Tuesday, March 10th, 2026

    Time: 5:00 p.m. Eastern time (3:00 p.m. Mountain time)

    Toll-free dial-in number: 1-800-717-1738

    International dial-in number: 1-646-307-1865

    Conference ID: 08247

    Please call the conference telephone number 5-10 minutes prior to the start time. An operator will register your name and organization. If you have any difficulty connecting with the conference call, please contact Gateway Group at 1-949-574-3860.

    The conference call will be broadcast live and available for replay here and via the Events section of the Nature's Sunshine website here.

    A replay of the conference call will be available after 8:00 p.m. Eastern time on the same day through Tuesday, March 24, 2026.

    Toll-free replay number: 1-844-512-2921

    International replay number: 1-412-317-6671

    Replay ID: 1108247

    About Nature's Sunshine Products

    Nature's Sunshine Products (NASDAQ:NATR), a global leader in manufacturing and marketing high-quality herbal and nutritional supplements, distributes its products in more than 40 countries worldwide. Additional information about the Company can be obtained at its website, www.naturessunshine.com. 

    CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

    This press release contains forward-looking statements regarding the Company's future business expectations, which are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may include, but are not limited to, statements relating to the Company's objectives, plans, strategies and financial results, including outlook for 2026 net sales and adjusted EBITDA. All statements (other than statements of historical fact) that address activities, events or developments that the Company intends, expects, projects, believes or anticipates will or may occur in the future are forward-looking statements. These statements are often characterized by terminology such as "believe," "hope," "may," "anticipate," "should," "intend," "plan," "will," "expect," "estimate," "project," "positioned," "strategy" and similar expressions, and are based on assumptions and assessments made by management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties, including the following:

    • failure to comply with laws and regulations relating to trade restrictions and export controls;
    • laws and regulations regarding direct selling that may prohibit or restrict our ability to sell our products in some markets or require us to make changes to our business model in some markets;
    • current and potential future extensive government regulations to which the Company's products, business practices and manufacturing activities are subject;
    • registration of products for sale in foreign markets, or difficulty or increased cost of importing products into foreign markets;
    • legal challenges to the Company's direct selling program or to the classification of its independent consultants;
    • failure of the Company's independent consultants to comply with advertising laws;
    • product liability claims;
    • impact of anti-bribery laws, including the U.S. Foreign Corrupt Practices Act;
    • the Company's ability to attract and retain independent consultants;
    • the loss of one or more key independent consultants who have a significant sales network;
    • potential for liability relating to the Company's full ownership of China business;
    • the effect of fluctuating foreign exchange rates;
    • liabilities and obligations arising from improper activity by the Company's independent consultants;
    • changes to the Company's independent consultant compensation plans;
    • geopolitical issues, conflicts or other global events;
    • negative consequences resulting from difficult economic conditions, including the availability of liquidity or the willingness of the Company's customers to purchase products;
    • risks associated with the manufacturing of the Company's products;
    • supply chain disruptions, manufacturing interruptions or delays or the failure to accurately forecast customer demand;
    • failure to timely and effectively obtain shipments of products from our suppliers and deliver products to our independent consultants and customers;
    • uncertainties relating to the application of transfer pricing, duties, value-added taxes and other tax regulations, and changes thereto;
    • failure to maintain an effective system of internal controls over financial reporting;
    • cybersecurity threats and exposure to data loss;
    • the storage, processing and use of data, some of which contain personal information, are subject to complex and evolving privacy and data protection laws and regulations;
    • reliance on information technology infrastructure; and
    • the sufficiency of trademarks and other intellectual property rights.

    These and other risks and uncertainties that could cause actual results to differ from predicted results are more fully detailed under the caption "Risk Factors" in our reports filed with the Securities and Exchange Commission, including our Annual Report on Form 10-K and Quarterly Reports filed on Form 10-Q.

    All forward-looking statements speak only as of the date of this press release and are expressly qualified in their entirety by the cautionary statements included in or incorporated by reference into this press release. Except as is required by law, the Company expressly disclaims any obligation to publicly release any revisions to forward-looking statements to reflect events after the date of this press release.

    Non-GAAP Financial Measures

    We have included information which has not been prepared in accordance with generally accepted accounting principles (GAAP), such as information concerning non-GAAP net income, adjusted EBITDA and net sales excluding the impact of foreign currency exchange fluctuations.

    We utilize the non-GAAP measures of non-GAAP net income and adjusted EBITDA in the evaluation of our operations and believe that these measures are useful indicators of our ability to fund our business. These non-GAAP financial measures should not be considered as an alternative to, or more meaningful than, U.S. GAAP net income (loss) as an indicator of our operating performance.

    Other companies may use the same or similarly named measures, but exclude different items, which may not provide investors with a comparable view of Nature's Sunshine Products' performance in relation to other companies. We have included a reconciliation of net income to adjusted EBITDA, the most comparable GAAP measure. We have also included a reconciliation of GAAP net income to non-GAAP net income and non-GAAP adjusted EPS, in the attached financial tables.

    Net sales in local currency removes, from net sales in U.S. dollars, the impact of changes in exchange rates between the U.S. dollar and the functional currencies of our foreign subsidiaries. This is accomplished by translating the current period net sales into U.S. dollars using the same foreign currency exchange rates that were used to translate the net sales for the previous comparable period.

    We believe presenting the impact of foreign currency fluctuations is useful to investors because it allows a more meaningful comparison of net sales of our foreign operations from period to period. Net sales excluding the impact of foreign currency fluctuations should not be considered in isolation or as an alternative to net sales in U.S. dollar measures that reflect current period exchange rates, or to other financial measures calculated and presented in accordance with U.S. GAAP.

    With respect to our Adjusted EBITDA outlook for the full year 2026, a quantitative reconciliation to the corresponding GAAP information cannot be provided without unreasonable effort because of the inherent difficulty of accurately forecasting the occurrence and financial impact of the various adjusting items necessary for such reconciliation that have not yet occurred, are out of our control, or cannot be reasonably predicted, including but not limited to warrant liabilities and stock based compensation. For the same reasons, we are unable to assess the probable significance of the unavailable information, which could have a material impact on our future GAAP financial results.

    Investor Relations:

    Gateway Group, Inc.

    Cody Slach

    1-949-574-3860

    [email protected] 

    NATURE'S SUNSHINE PRODUCTS, INC. AND SUBSIDIARIES

    CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

    (Amounts in thousands, except per share information)

    (Unaudited)

        
     Three Months Ended

    December 31,
     Year Ended

    December 31,
      2025   2024   2025   2024 
    Net sales$123,807  $118,205  $480,144  $454,364 
    Cost of sales (34,028)  (33,141)  (132,420)  (129,676)
    Gross profit 89,779   85,064   347,724   324,688 
            
    Operating expenses:       
    Volume incentives 36,039   36,805   144,591   140,589 
    Selling, general and administrative 48,418   43,709   178,390   164,004 
    Operating income 5,322   4,550   24,743   20,095 
    Other income (loss), net 165   (3,101)  5,069   (1,669)
    Income before provision for income taxes 5,487   1,449   29,812   18,426 
    Provision for income taxes 974   2,181   9,361   10,534 
    Net income (loss) 4,513   (732)  20,451   7,892 
    Net income (loss) attributable to noncontrolling interests 406   (411)  930   196 
    Net income (loss) attributable to common shareholders$4,107  $(321) $19,521  $7,696 
            
    Basic and diluted net income (loss) per common share:       
            
    Basic earnings (loss) per share attributable to common shareholders$0.23  $(0.02) $1.08  $0.41 
            
    Diluted earnings (loss) per share attributable to common shareholders$0.23  $(0.02) $1.06  $0.40 
            
    Weighted-average basic common shares outstanding 17,501   18,479   18,005   18,616 
    Weighted-average diluted common shares outstanding 17,922   18,479   18,468   19,089 
                    

    NATURE'S SUNSHINE PRODUCTS, INC. AND SUBSIDIARIES

    CONDENSED CONSOLIDATED BALANCE SHEETS

    (Amounts in thousands)

    (Unaudited)

    As of December 31, 2025   2024 
    Assets   
    Current assets:   
    Cash and cash equivalents$93,891  $84,700 
    Accounts receivable, net of allowance for doubtful accounts of $69 and $97, respectively 8,602   9,477 
    Inventories 68,312   59,443 
    Prepaid expenses and other 8,040   6,959 
    Total current assets 178,845   160,579 
    Property, plant and equipment, net 32,915   39,585 
    Operating lease right-of-use assets 17,600   12,799 
    Restricted investment securities - trading 1,132   915 
    Deferred income tax assets 20,068   17,644 
    Other assets 10,586   9,333 
    Total assets$261,146  $240,855 
        
    Liabilities and Shareholders' Equity   
    Current liabilities:   
    Accounts payable$8,021  $8,912 
    Accrued volume incentives and service fees 22,624   20,563 
    Accrued liabilities 34,080   25,399 
    Deferred revenue 5,840   2,774 
    Income taxes payable 4,703   4,117 
    Current portion of operating lease liabilities 3,270   3,927 
    Total current liabilities 78,538   65,692 
    Liability related to unrecognized tax benefits 428   628 
    Long-term portion of operating lease liabilities 15,630   10,277 
    Deferred compensation payable 1,132   915 
    Deferred income tax liabilities 954   1,007 
    Other liabilities 2,911   1,345 
    Total liabilities 99,593   79,864 
        
    Shareholders' equity:   
    Common stock, no par value; 50,000 shares authorized, 17,508 and 18,483 shares issued and outstanding as of December 31, 2025, and 2024, respectively 102,192   114,577 
    Retained earnings 76,928   57,407 
    Noncontrolling interest —   5,678 
    Accumulated other comprehensive loss (17,567)  (16,671)
    Total shareholders' equity 161,553   160,991 
    Total liabilities and shareholders' equity$261,146  $240,855 
            



    NATURE'S SUNSHINE PRODUCTS, INC. AND SUBSIDIARIES

    CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

    (Amounts in thousands)

    (Unaudited)

            
    Year Ended December 31, 2025   2024 
    CASH FLOWS FROM OPERATING ACTIVITIES:   
    Net income$20,451  $7,892 
    Adjustments to reconcile net income to net cash provided by operating activities:   
    Depreciation and amortization 13,844   14,219 
    Noncash lease expense 4,952   5,420 
    Share-based compensation expense 5,780   4,788 
    Loss on disposal or sale of property and equipment 397   1,570 
    Deferred income taxes (2,273)  (1,662)
    Purchase of trading investment securities (109)  (141)
    Proceeds from sale of trading investment securities 16   97 
    Realized and unrealized gains on investments (125)  (124)
    Foreign exchange (gains) losses (4,522)  1,700 
    Changes in operating assets and liabilities:   
    Accounts receivable 1,015   (1,121)
    Inventories (7,824)  5,562 
    Prepaid expenses and other (3,095)  528 
    Other assets 844   (560)
    Accounts payable (1,797)  1,085 
    Accrued volume incentives and service fees 1,500   (1,565)
    Accrued liabilities 8,502   (5,512)
    Deferred revenue 2,868   1,041 
    Lease liabilities (5,061)  (5,568)
    Income taxes payable (60)  (2,938)
    Liability related to unrecognized tax positions (200)  419 
    Deferred compensation payable 218   168 
    Net cash provided by operating activities 35,321   25,298 
    CASH FLOWS FROM INVESTING ACTIVITIES:   
    Purchases of property, plant and equipment (6,480)  (10,971)
    Net cash used in investing activities (6,480)  (10,971)
    CASH FLOWS FROM FINANCING ACTIVITIES:   
    Proceeds from revolving credit facility 5,087   40,991 
    Principal payments of revolving credit facility (5,087)  (40,991)
    Acquisition of nocontrolling interest (6,162)  — 
    Payments related to tax withholding for net-share settled equity awards (1,302)  (1,046)
    Repurchase of common stock (16,309)  (8,859)
    Net cash used in financing activities (23,773)  (9,905)
    Effect of exchange rates on cash and cash equivalents 4,123   (2,095)
    Net increase in cash and cash equivalents 9,191   2,327 
    Cash and cash equivalents at beginning of the year 84,700   82,373 
    Cash and cash equivalents at end of the year$93,891  $84,700 
    SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:   
    Cash paid for income taxes, net of refunds$12,547  $14,788 
    Cash paid for interest 98   119 

    NATURE'S SUNSHINE PRODUCTS, INC. AND SUBSIDIARIES

    RECONCILIATION OF NET INCOME (LOSS) TO ADJUSTED EBITDA

    (Amounts in thousands)

    (Unaudited)

     Three Months Ended

    December 31,
     Year Ended

    December 31,
      2025   2024   2025   2024
    Net income (loss)$4,513  $(732) $20,451  $7,892
    Adjustments:       
    Depreciation and amortization 3,306   4,024   13,844   14,219
    Share-based compensation expense 1,557   1,208   5,780   4,788
    Other (income) loss, net* (165)  3,101   (5,069)  1,669
    Provision for income taxes 974   2,181   9,361   10,534
    Other adjustments (1) 1,746   485   4,985   1,442
    Adjusted EBITDA$11,931  $10,267  $49,352  $40,544
            
            
    (1) Other adjustments       
    Other non-recurring expenses$1,746  $485  $4,985  $1,442
    Total adjustments$1,746  $485  $4,985  $1,442

    * Other (income) loss, net is primarily comprised of foreign exchange (gains) losses, interest income, and interest expense.

    NATURE'S SUNSHINE PRODUCTS, INC. AND SUBSIDIARIES

    RECONCILIATION OF GAAP NET INCOME (LOSS) TO

    NON-GAAP NET INCOME (LOSS) and NON-GAAP ADJUSTED EPS

    (Amounts in thousands)

    (Unaudited)

        
     Three Months Ended

    December 31,
     Year Ended

    December 31,
      2025   2024   2025   2024 
    Net income (loss)$4,513  $(732) $20,451  $7,892 
    Adjustments:       
    Loss on disposal of property and equipment —   —   —   — 
    Restructuring and other related expenses —   —   —   — 
    Other non-recurring expenses 1,746   485   4,985   1,442 
    VAT refund —   —   —   — 
    Tax impact of adjustments (436)  (121)  (1,246)  (276)
    Total adjustments 1,310   364   3,739   1,166 
    Non-GAAP net income (loss)$5,823  $(368) $24,190  $9,058 
            
    Reported net income (loss) attributable to common shareholders$4,107  $(321) $19,521  $7,696 
    Total adjustments 1,310   364   3,739   1,166 
    Non-GAAP net income attributable to common shareholders$5,417  $43  $23,260  $8,862 
            
    Basic income (loss) per share, as reported$0.23  $(0.02) $1.08  $0.41 
    Total adjustments, net of tax 0.07   0.02   0.21   0.06 
    Basic income per share, as adjusted$0.30  $—  $1.29  $0.47 
            
    Diluted income (loss) per share, as reported$0.23  $(0.02) $1.06  $0.40 
    Total adjustments, net of tax 0.07   0.02   0.20   0.06 
    Diluted income per share, as adjusted$0.30  $—  $1.26  $0.46 





    Primary Logo

    Get the next $NATR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NATR

    DatePrice TargetRatingAnalyst
    5/7/2025$19.00Buy
    DA Davidson
    9/13/2024$18.00Buy
    Canaccord Genuity
    3/9/2022$24.00 → $24.50Buy
    DA Davidson
    11/5/2021$22.00 → $24.00Buy
    DA Davidson
    10/15/2021$22.00Buy
    DA Davidson
    More analyst ratings

    $NATR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Nature's Sunshine Reports Strong Fourth Quarter and Full Year 2025 Financial Results

    LEHI, Utah, March 10, 2026 (GLOBE NEWSWIRE) -- Nature's Sunshine Products, Inc. (NASDAQ:NATR) ("Nature's Sunshine" and/or the "Company"), a global leader in manufacturing and marketing high-quality herbal and nutritional supplements, reported financial results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter 2025 Financial Summary vs. Same Year-Ago Quarter Net sales were up 4.7% to $123.8 million compared to $118.2 million (up 3.8% in constant currency).GAAP net income attributable to common shareholders of $4.1 million, or $0.23 per diluted share, compared to net loss of $0.3 million, or $(0.02) per diluted share.Adjusted EBITDA up 16% to $11.9 million compar

    3/10/26 4:05:00 PM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nature's Sunshine Sets Fourth Quarter 2025 Conference Call for Tuesday, March 10, 2026, at 5:00 p.m. ET

    LEHI, Utah, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Nature's Sunshine Products, Inc. (NASDAQ:NATR) ("Nature's Sunshine") (the "Company"), a leading manufacturer of high-quality herbal and nutritional supplements, will conduct a conference call on Tuesday, March 10, 2026, at 5:00 p.m. Eastern time (3:00 p.m. Mountain time) to discuss its financial results for the fourth quarter and full year ended December 31, 2025. The Company will report its financial results in a press release prior to the conference call. Nature's Sunshine CEO Kenneth Romanzi and CFO Shane Jones will host the conference call, followed by a question and answer period. Date: Tuesday, March 10, 2026Time: 5:00 p.m. Eastern time

    2/24/26 4:05:00 PM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Euromonitor International Names Synergy Pro-Argi-9+ the World's #1 L-Arginine Supplement

    LEHI, Utah, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Synergy Worldwide, a division of Nature's Sunshine Products, today announced that Euromonitor International has named Pro-Argi-9+ the world's #1 l-arginine supplement,* reinforcing the product's growing global momentum and Synergy's leadership in the health and wellness space. Synergy's flagship product, Pro-Argi-9+ offers a unique formula with clinically researched ingredients featuring L-Arginine to support nitric oxide production and promote healthy circulation and blood flow throughout the body. With this certification, Pro-Argi-9+ will continue to serve as the cornerstone of Synergy's mission to help people push the boundaries of their po

    12/15/25 8:00:00 AM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NATR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Nature's Sunshine Products Inc.

    4 - NATURES SUNSHINE PRODUCTS INC (0000275053) (Issuer)

    3/10/26 5:42:18 PM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP & President, North America Herbert Kevin R. covered exercise/tax liability with 368 shares, was granted 7,124 shares and converted options into 1,239 shares, increasing direct ownership by 19% to 50,610 units (SEC Form 4)

    4 - NATURES SUNSHINE PRODUCTS INC (0000275053) (Issuer)

    3/10/26 5:41:47 PM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Nature's Sunshine Products Inc.

    4 - NATURES SUNSHINE PRODUCTS INC (0000275053) (Issuer)

    3/10/26 5:40:02 PM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NATR
    SEC Filings

    View All

    SEC Form 10-K filed by Nature's Sunshine Products Inc.

    10-K - NATURES SUNSHINE PRODUCTS INC (0000275053) (Filer)

    3/10/26 5:10:54 PM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nature's Sunshine Products Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Leadership Update, Financial Statements and Exhibits

    8-K - NATURES SUNSHINE PRODUCTS INC (0000275053) (Filer)

    3/10/26 5:00:59 PM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Nature's Sunshine Products Inc.

    10-Q - NATURES SUNSHINE PRODUCTS INC (0000275053) (Filer)

    11/6/25 5:11:13 PM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NATR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    DA Davidson resumed coverage on Nature's Sunshine with a new price target

    DA Davidson resumed coverage of Nature's Sunshine with a rating of Buy and set a new price target of $19.00

    5/7/25 8:37:48 AM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Canaccord Genuity initiated coverage on Nature's Sunshine with a new price target

    Canaccord Genuity initiated coverage of Nature's Sunshine with a rating of Buy and set a new price target of $18.00

    9/13/24 7:38:59 AM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    DA Davidson reiterated coverage on Natures Sunshine Products with a new price target

    DA Davidson reiterated coverage of Natures Sunshine Products with a rating of Buy and set a new price target of $24.50 from $24.00 previously

    3/9/22 9:23:08 AM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NATR
    Leadership Updates

    Live Leadership Updates

    View All

    Nature's Sunshine Appoints Erich Fritz as Executive Vice President of Global Supply Chain

    LEHI, Utah, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Nature's Sunshine Products, Inc. (NASDAQ:NATR) ("Nature's Sunshine") (the "Company"), a leading manufacturer of high-quality herbal and nutritional supplements, today announced that Erich Fritz has been named Executive Vice President, Global Supply Chain, effective December 8, 2025. Mr. Fritz will report directly to Ken Romanzi, the Company's Chief Executive Officer. Mr. Fritz brings over 40 years of executive experience in operations, supply chain, and business development, with a proven track record of driving growth, operational efficiency, and innovation at leading consumer goods companies. His leadership spans Fortune 500 organizations an

    12/4/25 10:00:00 AM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nature's Sunshine Appoints Kenneth Romanzi as CEO

    Mr. Romanzi Brings Extensive Leadership and Operational Experience at Prominent, Large-Scale Consumer Packaged Goods Companies and Proven Track Record of Driving Growth and Value Creation LEHI, Utah, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Nature's Sunshine Products, Inc. (NASDAQ:NATR) ("Nature's Sunshine") (the "Company"), a leading manufacturer of high-quality herbal and nutritional supplements, today announced that its Board of Directors has appointed Kenneth Romanzi to succeed Terrence Moorehead as Chief Executive Officer. Mr. Romanzi will assume the role and become a member of the Nature's Sunshine Board of Directors on October 29, 2025. Mr. Romanzi is an experienced CEO and operator with

    10/15/25 9:00:00 AM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nature's Sunshine Announces Leadership Transition Plan

    Board Initiates CEO Search Process Terrence Moorehead to Step Down as President and CEO, Once Successor Appointed Company Reaffirms Full Year 2025 Outlook LEHI, Utah, June 02, 2025 (GLOBE NEWSWIRE) -- Nature's Sunshine Products, Inc. (NASDAQ:NATR) ("Nature's Sunshine") (the "Company"), a leading manufacturer of high-quality herbal and nutritional supplements, today announced that Terrence Moorehead has notified the Company's Board of Directors (the "Board") of his decision to step down as President and Chief Executive Officer, effective upon the appointment of a successor. At that time, Mr. Moorehead will also resign as a member of the Board of Directors. The Nature's Sunshine Board ha

    6/2/25 9:00:00 AM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NATR
    Financials

    Live finance-specific insights

    View All

    Nature's Sunshine Reports Strong Fourth Quarter and Full Year 2025 Financial Results

    LEHI, Utah, March 10, 2026 (GLOBE NEWSWIRE) -- Nature's Sunshine Products, Inc. (NASDAQ:NATR) ("Nature's Sunshine" and/or the "Company"), a global leader in manufacturing and marketing high-quality herbal and nutritional supplements, reported financial results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter 2025 Financial Summary vs. Same Year-Ago Quarter Net sales were up 4.7% to $123.8 million compared to $118.2 million (up 3.8% in constant currency).GAAP net income attributable to common shareholders of $4.1 million, or $0.23 per diluted share, compared to net loss of $0.3 million, or $(0.02) per diluted share.Adjusted EBITDA up 16% to $11.9 million compar

    3/10/26 4:05:00 PM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nature's Sunshine Sets Fourth Quarter 2025 Conference Call for Tuesday, March 10, 2026, at 5:00 p.m. ET

    LEHI, Utah, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Nature's Sunshine Products, Inc. (NASDAQ:NATR) ("Nature's Sunshine") (the "Company"), a leading manufacturer of high-quality herbal and nutritional supplements, will conduct a conference call on Tuesday, March 10, 2026, at 5:00 p.m. Eastern time (3:00 p.m. Mountain time) to discuss its financial results for the fourth quarter and full year ended December 31, 2025. The Company will report its financial results in a press release prior to the conference call. Nature's Sunshine CEO Kenneth Romanzi and CFO Shane Jones will host the conference call, followed by a question and answer period. Date: Tuesday, March 10, 2026Time: 5:00 p.m. Eastern time

    2/24/26 4:05:00 PM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nature's Sunshine Reports Strong Third Quarter 2025 Results

    Net Sales up 12% to $128.3 Million, GAAP EPS up 30% to $0.30Adjusted EBITDA up 42% to $15.2 MillionRaised Full-Year Outlook LEHI, Utah, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Nature's Sunshine Products, Inc. (NASDAQ:NATR) ("Nature's Sunshine"), a leading manufacturer of high-quality herbal and nutritional supplements, reported financial results for the third quarter ended September 30, 2025. Third Quarter 2025 Financial Summary vs. Same Year-Ago Quarter Net sales were up 12% to $128.3 million compared to $114.6 million (up 10% in constant currency).Gross profit margin increased 200 basis points to 73.3% compared to 71.3%.GAAP net income attributable to common shareholders was $5.3 million, o

    11/6/25 4:05:00 PM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NATR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Nature's Sunshine Products Inc. (Amendment)

    SC 13G/A - NATURES SUNSHINE PRODUCTS INC (0000275053) (Subject)

    2/12/24 10:37:49 AM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Nature's Sunshine Products Inc. (Amendment)

    SC 13G/A - NATURES SUNSHINE PRODUCTS INC (0000275053) (Subject)

    1/31/24 11:56:05 AM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Nature's Sunshine Products Inc. (Amendment)

    SC 13G/A - NATURES SUNSHINE PRODUCTS INC (0000275053) (Subject)

    2/13/23 2:42:04 PM ET
    $NATR
    Biotechnology: Pharmaceutical Preparations
    Health Care